Sign up for tax alert emails    GTNU homepage    Tax newsroom    Email document    Print document    Download document

September 2, 2021

Report on recent US international tax developments 2 September 2021

The FY 2022 Budget resolution that has now passed both the United States (US) Senate and the House includes reconciliation instructions to various committees to report provisions under their jurisdictions by 15 September, though there is no penalty for missing the deadline. The House Ways and Means Committee will begin a markup the week of 6 September, which likely will continue over a period of days. The ultimate size of the proposed US$3.5 trillion reconciliation bill remains unclear at this time, with the amount of investments ultimately dictating the amount of pay-fors, including expected tax increases.

The House returns from the August recess on 20 September. The Senate returns to Washington on 13 September.

In a recent Chief Counsel Advice Memorandum (CCA 202132009), the Internal Revenue Service (IRS) concluded that an affiliated group's joint and several liability for the payment of a branded prescription drug fee is not solely determinative in deciding whether the remitting member may exclude any reimbursement of the fee from its gross income. The IRS provided several factors that should be considered in determining whether the remitting member benefits from the payment of the fee and, therefore, may not exclude the reimbursement from its gross income.

The taxpayer is a US corporation and member of an affiliated group that develops, manufactures and distributes branded drugs and other medical care products. The foreign members of the group manufacture the drugs and own the intellectual property related to the branded drugs. Under an intercompany agreement with the foreign members, the taxpayer distributes the drugs in the United States and receives a fixed profit margin resulting from the sales. The taxpayer's transfer pricing method allocates excess profits or losses beyond the specified operating profit margin to the foreign members.

The five-factor test articulated in the CCA is helpful because it provides insight as to how the IRS may analyze intracompany reimbursements. The five-factor test does not articulate new principles; instead, it distills authorities from the reimbursement doctrine, capital contribution principles, and direct-and-proximate-benefit principles on which taxpayers rely when analyzing reimbursement payments. Although the CCA focused on whether a reimbursement was includible in gross income, the five-factor test may also be helpful in determining whether the reimbursing party or the party receiving the reimbursement may claim a deduction for the reimbursed expense.

The US and France recently signed a joint statement on the spontaneous exchange of country-by-country reports for fiscal years beginning in 2020 and 2021. The exchange will be based on Article 27 of the 1994 US-France income tax treaty, as amended by protocols signed in 2004 and 2009.


For additional information with respect to this Alert, please contact the following:

Ernst & Young LLP (United States), International Tax and Transaction Services, Washington, DC


The information contained herein is general in nature and is not intended, and should not be construed, as legal, accounting or tax advice or opinion provided by Ernst & Young LLP to the reader. The reader also is cautioned that this material may not be applicable to, or suitable for, the reader's specific circumstances or needs, and may require consideration of non-tax and other tax factors if any action is to be contemplated. The reader should contact his or her Ernst & Young LLP or other tax professional prior to taking any action based upon this information. Ernst & Young LLP assumes no obligation to inform the reader of any changes in tax laws or other factors that could affect the information contained herein.


Copyright © 2024, Ernst & Young LLP.


All rights reserved. No part of this document may be reproduced, retransmitted or otherwise redistributed in any form or by any means, electronic or mechanical, including by photocopying, facsimile transmission, recording, rekeying, or using any information storage and retrieval system, without written permission from Ernst & Young LLP.


Any U.S. tax advice contained herein was not intended or written to be used, and cannot be used, by the recipient for the purpose of avoiding penalties that may be imposed under the Internal Revenue Code or applicable state or local tax law provisions.


"EY" refers to the global organisation, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.


Privacy  |  Cookies  |  BCR  |  Legal  |  Global Code of Conduct Opt out of all email from EY Global Limited.


Cookie Settings

This site uses cookies to provide you with a personalized browsing experience and allows us to understand more about you. More information on the cookies we use can be found here. By clicking 'Yes, I accept' you agree and consent to our use of cookies. More information on what these cookies are and how we use them, including how you can manage them, is outlined in our Privacy Notice. Please note that your decision to decline the use of cookies is limited to this site only, and not in relation to other EY sites or Please refer to the privacy notice/policy on these sites for more information.

Yes, I accept         Find out more